ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ VÀ TÁC DỤNG KHÔNG MONG MUỐN CỦA SECUKINUMAB 300 MG TRÊN NGƯỜI BỆNH VẢY NẾN THÔNG THƯỜNG MỨC ĐỘ TRUNG BÌNH - NẶNG TẠI BỆNH VIỆN DA LIỄU HÀ NỘI

Abstract

Objective: To evaluate the treatment results and adverse effects of the Secukinumab 300 mg subcutaneous injection regimen in the treatment of moderate-severe psoriasis vulgaris at Hanoi Dermatology Hospital from April 2024 to September 2025. Subjects and methods: Non-controlled clinical intervention study on 36 patients with moderate-severe psoriasis vulgaris treated with Secukinumab 300 mg subcutaneous injection at weeks 0, 1, 2, 3, 4, 8, 12, 16. Evaluate treatment response through PASI, BSA, DLQI index and record adverse effects within 16 weeks. Results: PASI, BSA and DLQI indexes gradually decreased during 16 weeks of treatment, the difference was statistically significant with p<0.05. Treatment results based on PASI 75 index were often observed clearly at week 3 (33.3%) and increased continuously until week 12 (100%), remaining stable until week 16. PASI 90 and PASI 100 response rates were achieved from week 4 and increased continuously with corresponding rates of 88.9% and 36.1% at week 16. There were 3 cases (8.3%) with adverse effects, including fatigue (2.8%), nasopharyngitis (5.6%). Conclusion: Secukinumab 300 mg subcutaneous injection regimen is a treatment with few adverse effects in the treatment of patients with moderate-to-severe psoriasis vulgaris